SEARCH:   Advanced

Blood, 15 October 2007, Vol. 110, No. 8, pp. 3064-3070. Prepublished online as a Blood First Edition Paper on June 14, 2007; DOI 10.1182/blood-2007-04-067215. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-04-067215v1 110/8/3064    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brunstein, C. G. Articles by Wagner, J. E. Search for Related Content PubMed PubMed Citation Articles by Brunstein, C. G. Articles by Wagner, J. E. Related Collections Transplantation Clinical Trials and Observations Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease Claudio G. Brunstein1,2, Juliet N. Barker1,2, Daniel J. Weisdorf1,2, Todd E. DeFor1,3, Jeffrey S. Miller1,2, Bruce R. Blazar1,3, Philip B. McGlave1,2, and John E. Wagner1,3 1 Blood and Marrow Transplant Program and Divisions of 2 Medical Hematology, Oncology, and Transplantation and 3 Pediatric Hematology and Oncology, University of Minnesota, Minneapolis We evaluated the efficacy of umbilical cord blood (UCB) in the setting of a nonmyeloablative regimen consisting of fludarabine (200 mg/m2), cyclophosphamide (50 mg/kg), and a single fraction of total body irradiation (200 cGy) with cyclosporine and mycophenolate mofetil for posttransplantation immunoprophylaxis. The target cell dose for the UCB graft was 3.0 x 107 nucleated cells/kg, resulting in the selection of a second partially human leukocyte antigen-matched UCB unit in 85%. One hundred ten patients with hematologic disease were enrolled. Neutrophil recovery was achieved in 92% at a median of 12 days. Incidences of grades III and IV acute and chronic graft-versus-host disease (GVHD) were 22% and 23%, respectively. Transplantation-related mortality was 26% at 3 years. Survival and event-free survival (EFS) at 3 years were 45% and 38%, respectively. Favorable risk factors for survival were absence of high-risk clinical features (Karnofsky 50-60, serious organ dysfunction, recent fungal infection, P < .01) and absence of severe GVHD (P = .04), and favorable risk factors for EFS were absence of high-risk clinical features (P < .01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Are 2 cords better than 1? Elizabeth Shpall, Marcos de Lima, Roy Jones, and Richard Champlin Blood 2007 110: 2789-2790. [Full Text] [PDF] This article has been cited by other articles: D. M. Weinstock, C. Case Jr, J. L. Bader, N. J. Chao, C. N. Coleman, R. J. Hatchett, D. J. Weisdorf, and D. L. Confer Radiologic and nuclear events: contingency planning for hematologists/oncologists Blood, June 15, 2008; 111(12): 5440 - 5445. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020